{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:03:06Z","timestamp":1788624186210,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10528-020-09961-2","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T08:05:33Z","timestamp":1586419533000},"page":"473-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression"],"prefix":"10.1007","volume":"58","author":[{"given":"Takayuki","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Uetsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Murodumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"9961_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131157","journal-title":"J Oral Maxillofac Surg"},{"key":"9961_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/cncr.21130","volume":"104","author":"CA Migliorati","year":"2005","unstructured":"Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83\u201393. https:\/\/doi.org\/10.1002\/cncr.21130","journal-title":"Cancer"},{"key":"9961_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","volume":"68","author":"TL Aghaloo","year":"2010","unstructured":"Aghaloo TL, Felsenfeld AL, Tetradis S (2010) Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 68:959\u2013963. https:\/\/doi.org\/10.1016\/j.joms.2009.10.010","journal-title":"J Oral Maxillofac Surg"},{"key":"9961_CR4","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"key":"9961_CR5","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","volume":"26","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G III, Huryn JM (2008) Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26:4037\u20134038. https:\/\/doi.org\/10.1200\/JCO.2007.15.5424","journal-title":"J Clin Oncol"},{"key":"9961_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/039463201202500328","volume":"25","author":"P Brunamonti Binello","year":"2012","unstructured":"Brunamonti Binello P, Bandelloni R, Labanca M, Buffoli B, Rezzani R, Rodella LF (2012) Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol 25:789\u2013791. https:\/\/doi.org\/10.1177\/039463201202500328","journal-title":"Int J Immunopathol Pharmacol"},{"key":"9961_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","volume":"15","author":"FP Koch","year":"2011","unstructured":"Koch FP, Walter C, Hansen T, Jager E, Wagner W (2011) Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15:63\u201366. https:\/\/doi.org\/10.1007\/s10006-010-0224-y","journal-title":"Oral Maxillofac Surg"},{"key":"9961_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","volume":"113","author":"Y Fleissig","year":"2012","unstructured":"Fleissig Y, Regev E, Lehman H (2012) Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 113:e1\u2013e3. https:\/\/doi.org\/10.1016\/j.tripleo.2011.06.023","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"9961_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.archoralbio.2014.09.012","volume":"60","author":"T Nakagawa","year":"2015","unstructured":"Nakagawa T, Ohta K, Kubozono K, Ishida Y, Naruse T, Takechi M, Kamata N (2015) Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch Oral Biol 60:557\u2013565. https:\/\/doi.org\/10.1016\/j.archoralbio.2014.09.012","journal-title":"Arch Oral Biol"},{"key":"9961_CR10","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.febslet.2008.08.023","volume":"582","author":"H Hayashi","year":"2008","unstructured":"Hayashi H, Nakahama K, Sato T, Tuchiya T, Asakawa Y, Maemura T, Tanaka M, Morita M, Morita I (2008) The role of Mac-1 (CD11b\/CD18) in osteoclast differentiation induced by receptor activator of nuclear factor-kappaB ligand. FEBS Lett 582:3243\u20133248. https:\/\/doi.org\/10.1016\/j.febslet.2008.08.023","journal-title":"FEBS Lett"},{"key":"9961_CR11","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1111\/jcmm.13254","volume":"21","author":"G Yang","year":"2017","unstructured":"Yang G, Chen X, Yan Z, Zhu Q, Yang C (2017) CD11b promotes the differentiation of osteoclasts induced by RANKL through the spleen tyrosine kinase signalling pathway. J Cell Mol Med 21:3445\u20133452. https:\/\/doi.org\/10.1111\/jcmm.13254","journal-title":"J Cell Mol Med"},{"key":"9961_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/PL00008475","volume":"126","author":"B Winding","year":"2000","unstructured":"Winding B, Misander H, Sveigaard C, Therkildsen B, Jakobsen M, Overgaard T, Oursler MJ, Foged NT (2000) Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis. J Cancer Res Clin Oncol 126:631\u2013640","journal-title":"J Cancer Res Clin Oncol"},{"key":"9961_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1359\/jbmr.2001.16.6.1077","volume":"16","author":"G van der Pluijm","year":"2001","unstructured":"van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C (2001) Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 16:1077\u20131091. https:\/\/doi.org\/10.1359\/jbmr.2001.16.6.1077","journal-title":"J Bone Miner Res"},{"key":"9961_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1210\/edrv.19.1.0323","volume":"19","author":"TA Guise","year":"1998","unstructured":"Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19:18\u201354. https:\/\/doi.org\/10.1210\/edrv.19.1.0323","journal-title":"Endocr Rev"},{"key":"9961_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","volume":"18","author":"N Ferrara","year":"1997","unstructured":"Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4\u201325. https:\/\/doi.org\/10.1210\/edrv.18.1.0287","journal-title":"Endocr Rev"},{"key":"9961_CR16","first-page":"59","volume":"237","author":"M Shibuya","year":"1999","unstructured":"Shibuya M, Ito N, Claesson-Welsh L (1999) Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 237:59\u201383","journal-title":"Curr Top Microbiol Immunol"},{"key":"9961_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10555-007-9071-1","volume":"26","author":"RJ Epstein","year":"2007","unstructured":"Epstein RJ (2007) VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 26:443\u2013452. https:\/\/doi.org\/10.1007\/s10555-007-9071-1","journal-title":"Cancer Metastasis Rev"},{"key":"9961_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434. https:\/\/doi.org\/10.1056\/NEJMoa021491","journal-title":"N Engl J Med"},{"key":"9961_CR19","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"key":"9961_CR20","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676. https:\/\/doi.org\/10.1056\/NEJMoa072113","journal-title":"N Engl J Med"},{"key":"9961_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"key":"9961_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SIS Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"9961_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1084\/jem.190.2.293","volume":"190","author":"S Niida","year":"1999","unstructured":"Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Nishikawa S, Kodama H (1999) Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190:293\u2013298. https:\/\/doi.org\/10.1084\/jem.190.2.293","journal-title":"J Exp Med"},{"key":"9961_CR24","doi-asserted-by":"publisher","first-page":"e0124909","DOI":"10.1371\/journal.pone.0124909","volume":"10","author":"HR Kim","year":"2015","unstructured":"Kim HR, Kim KW, Kim BM, Cho ML, Lee SH (2015) The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS ONE 10:e0124909. https:\/\/doi.org\/10.1371\/journal.pone.0124909","journal-title":"PLoS ONE"},{"key":"9961_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jss.2008.01.031","volume":"151","author":"J Yamada","year":"2009","unstructured":"Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, Okaji Y, Shuno Y, Nishikawa T, Tanaka J, Takahashi K, Nagawa H (2009) Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 151:115\u2013120. https:\/\/doi.org\/10.1016\/j.jss.2008.01.031","journal-title":"J Surg Res"},{"key":"9961_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","volume":"15","author":"T Ziebart","year":"2011","unstructured":"Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D, Al-Nawas B, Walter C (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105\u2013111. https:\/\/doi.org\/10.1007\/s00784-009-0365-2","journal-title":"Clin Oral Investig"},{"key":"9961_CR27","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538\u20136544","journal-title":"Cancer Res"},{"key":"9961_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","volume":"44","author":"M Di Salvatore","year":"2011","unstructured":"Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, Astone A, Barone C (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44:139\u2013146. https:\/\/doi.org\/10.1111\/j.1365-2184.2011.00745.x","journal-title":"Cell Prolif"},{"key":"9961_CR29","doi-asserted-by":"publisher","first-page":"84248","DOI":"10.18632\/oncotarget.20539","volume":"8","author":"XJ Cai","year":"2017","unstructured":"Cai XJ, Wang Z, Cao JW, Ni JJ, Xu YY, Yao J, Xu H, Liu F, Yang GY (2017) Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer. Oncotarget 8:84248\u201384257. https:\/\/doi.org\/10.18632\/oncotarget.20539","journal-title":"Oncotarget"},{"key":"9961_CR30","first-page":"2893","volume":"9","author":"D Santini","year":"2003","unstructured":"Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893\u20132897","journal-title":"Clin Cancer Res"},{"key":"9961_CR31","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1535-7163.MCT-07-0311","volume":"6","author":"C Scavelli","year":"2007","unstructured":"Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A (2007) Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 6:3256\u20133262","journal-title":"Mol Cancer Ther"},{"key":"9961_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","volume":"376","author":"F Shalaby","year":"1995","unstructured":"Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62\u201366. https:\/\/doi.org\/10.1038\/376062a0","journal-title":"Nature"},{"key":"9961_CR33","doi-asserted-by":"publisher","first-page":"31273","DOI":"10.1074\/jbc.273.47.31273","volume":"273","author":"S Ogawa","year":"1998","unstructured":"Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M (1998) A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR\/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273:31273\u201331282. https:\/\/doi.org\/10.1074\/jbc.273.47.31273","journal-title":"J Biol Chem"},{"key":"9961_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s0092-8674(00)81010-7","volume":"98","author":"P Carmeliet","year":"1999","unstructured":"Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oosthuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert JM, Collen D, Dejana E (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147\u2013157. https:\/\/doi.org\/10.1016\/s0092-8674(00)81010-7","journal-title":"Cell"},{"key":"9961_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0014-5793(00)01520-9","volume":"473","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161\u2013164. https:\/\/doi.org\/10.1016\/s0014-5793(00)01520-9","journal-title":"FEBS Lett"},{"key":"9961_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.matbio.2008.06.005","volume":"27","author":"Q Yang","year":"2008","unstructured":"Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L, Hauschka PV (2008) VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 27:589\u2013599. https:\/\/doi.org\/10.1016\/j.matbio.2008.06.005","journal-title":"Matrix Biol"},{"key":"9961_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s10637-012-9845-3","volume":"31","author":"A Garcia-Gomez","year":"2013","unstructured":"Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M (2013) RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications Investig New Drugs 31:200\u2013205. https:\/\/doi.org\/10.1007\/s10637-012-9845-3","journal-title":"Therapeutic implications Investig New Drugs"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-020-09961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10528-020-09961-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-020-09961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:13:30Z","timestamp":1617923610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10528-020-09961-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["9961"],"URL":"https:\/\/doi.org\/10.1007\/s10528-020-09961-2","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and\/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}